Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

63.28 +0.50 (+0.80%)
Streaming Delayed Price Updated: 10:02 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tarsus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay ↗
Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA). 
Via Benzinga
News headline image
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4 ↗
Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug,... 
Via Benzinga
News headline image
Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharma Touts Positive Data For Experimental Drug For Tick-Borne Disease ↗
 
Via Benzinga
News headline image
Tarsus to Present at Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Bio-Pharma Company OKYO Pharma Tackles A Common Eye Disease For Which The Current Treatments Aren't Effective Enough ↗
An eye condition that has been described as a stealth disease currently affects as many as 49 million Americans. Dry Eye Disease (DED) afflicts over one-third of Americans over 50 and... 
Via Benzinga
News headline image
Tarsus Added to NASDAQ Biotechnology Index
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Announces Transition Plans for Board of Directors
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
Tuesday's session saw 211 companies set new 52-week lows. 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
31 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) climbed 64.9% to $9.86. Redbox recently reported CFO transition. SoundHound AI, Inc. (NASDAQ: SOUN) shares gained 30.5% to $8.48... 
Via Benzinga
News headline image
66 Biggest Movers From Yesterday ↗
Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged... 
Via Benzinga
News headline image
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More ↗
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
Via Benzinga
News headline image
Looking Into Tarsus Pharmaceuticals's Return On Capital Employed ↗
According to Benzinga Pro data, during Q4, Tarsus Pharmaceuticals (NASDAQ:TARS) posted sales of $338.00 thousand. Earnings were up 5.39%, but Tarsus Pharmaceuticals still reported... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
During Thursday's morning trading, 152 companies set new 52-week lows. Noteworthy Points From Today's 52-Week Lows: Rivian Automotive (NASDAQ:RIVN) was the largest... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers Statera BioPharma (NASDAQ:STAB) shares increased by 16.92% to $3.16 during Wednesday's regular session. The market value of their outstanding shares is at $87.... 
Via Benzinga
News headline image
2 Biotech Stocks Wall Street Predicts Will Double ↗
Biotechnology is advancing rapidly, driven by robust investments in new developments and a demand for synthetic biology. The industry is expected to continue to generate significant growth over an... 
Via Talk Markets
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 23, 2021 ↗
Upgrades Keefe, Bruyette & Woods upgraded the previous rating for CBRE Group Inc (NYSE: 
Via Benzinga
News headline image
3 Top Biotech Stocks to Buy Right Now ↗
These three biotech stocks recently had positive news coming out of phase 2 trials, making them good choices for growth-oriented investors. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Anavex Life Sciences (NASDAQ:AVXL) stock increased by 17.07% to $25.92 during Tuesday's regular session. As of 12:33 EST, this security is trading at a volume... 
Via Benzinga
News headline image
48 Biggest Movers From Yesterday ↗
Gainers Lydall, Inc. (NYSE: LDL) shares jumped 85.4% to close at $61.72 on Monday after the company agreed to be acquired by Unifrax for $61.10 per share. New Concept Energy,... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Dow Jumps Over 500 Points; Lydall Shares Spike Higher ↗
Toward the end of trading Monday, the Dow traded up 1.71% to 33,857.87 while the NASDAQ rose 0.63% to 14,119.16. The S&P also rose, gaining 1.28% to 4,219.92. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Anavex Life Sciences (NASDAQ:AVXL) shares moved upwards by 17.07% to $25.92 during Monday's regular session. Anavex Life Sciences's stock is trading at a... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.